Harvard Bioscience INC

Harvard Bioscience stockholders approved amendments to the company's Incentive Plan and Employee Stock Purchase Plan, increasing authorized shares.

Harvard Bioscience presented an investor overview detailing a strategic shift towards translational science tools, financial restructuring, and operational efficiencies aimed at driving future growth.

Harvard Bioscience reported first quarter 2026 results with revenues of $20.8 million, a slight decrease year-over-year, but saw gross margin expand to 59% and reaffirmed full-year guidance.

Harvard Bioscience details its strategic shift to translational science tools, highlighting strong FY25 adjusted financial performance and positive FY26 outlook.

Harvard Bioscience announced its fourth quarter and full-year 2025 financial results, alongside 2026 guidance and the permanent appointment of Mark Frost as CFO.

Harvard Bioscience stockholders approved a 1-for-10 reverse stock split to regain Nasdaq minimum bid price compliance.

Harvard Bioscience reports significant Q3 2025 losses, faces substantial doubt about its going concern status, and navigates Nasdaq delisting threats amid ongoing debt refinancing efforts.

Harvard Bioscience reported a significant net loss driven by a goodwill impairment and faces substantial doubt about its ability to continue as a going concern due to debt obligations and Nasdaq delisting risk.

Harvard Bioscience's Q1 2025 results reveal a net loss of $50.34 million and highlight substantial doubt about the company's ability to continue as a going concern due to debt refinancing challenges.

Harvard Bioscience experienced a significant revenue decrease in Q3 2024, leading to a net loss and challenges with debt covenants.

Harvard Bioscience's Q2 2024 results show a decrease in revenue compared to the same period last year, impacted by softening global demand and reduced sales to contract research organizations.

Harvard Bioscience reported a decrease in revenue and a net loss for the first quarter of 2024, impacted by softening global demand and other factors.

Harvard Bioscience, Inc. reported a significant net loss in 2025, driven by goodwill impairment and declining revenues, while initiating a major manufacturing consolidation and debt refinancing.

Harvard Bioscience's 2024 10-K filing reveals substantial doubt about the company's ability to continue as a going concern due to a debt covenant breach and the need to refinance its credit agreement by June 30, 2025.

Harvard Bioscience's 2023 annual report reveals a slight revenue decrease but improved gross profit margins, alongside strategic shifts and restructuring efforts.

Harvard Bioscience director Katherine A. Eade was granted 16,556 restricted stock units as part of standard equity compensation.

Harvard Bioscience Director William Snider reported the acquisition of 16,556 restricted stock units.

Stephen J. DeNelsky, a Director at Harvard Bioscience Inc., reported the acquisition of 16,556 restricted stock units.

Robert E. Gagnon, a Director at Harvard Bioscience Inc., was granted 16,556 restricted stock units, vesting prior to the next annual meeting or one year from grant.

Harvard Bioscience, Inc. reports a Form 4 filing detailing the acquisition of restricted stock units by Director Seth Benson.

Harvard Bioscience CFO Mark Frost reported the acquisition of 30,000 restricted stock units and updated his total beneficial ownership to 47,500 shares following a recent reverse stock split.

Harvard Bioscience schedules its 2026 Annual Meeting of Stockholders for June 2, 2026, to vote on director elections, executive compensation, and equity plan amendments.

Harvard Bioscience, Inc. will hold a Special Meeting on March 6, 2026, to seek stockholder approval for a reverse stock split to maintain its Nasdaq listing.

Harvard Bioscience, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Harvard Bioscience will hold its 2025 Annual Meeting of Stockholders virtually on June 2, 2025, to vote on director election, auditor ratification, executive compensation, and an amended incentive plan.

Harvard Bioscience, Inc. has filed a definitive proxy statement with the SEC.

Harvard Bioscience announces its 2024 Annual Meeting of Stockholders to be held virtually on May 14, 2024, to vote on director election, auditor ratification, executive compensation, and other business.

BroadOak Income Fund and affiliates have provided Harvard Bioscience with a $45 million loan facility, gaining substantial equity interest and a board seat.

Leviticus Partners LP has increased its beneficial ownership of Harvard Bioscience Inc. common stock to 6.5%, acquiring 293,676 shares.

Leviticus Partners LP has disclosed a 7.6% beneficial ownership stake in Harvard Bioscience Inc., holding 3,401,601 common shares.

Leviticus Partners LP has filed an amended Schedule 13G, reporting beneficial ownership of 7.5% of Harvard Bioscience Inc.'s common stock.

Leviticus Partners LP and AMH Equity LLC have increased their beneficial ownership in Harvard Bioscience Inc. to 9.2% of common stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 2.5% in Harvard Bioscience Inc.'s common stock as of June 30, 2025.

Leviticus Partners LP and AMH Equity LLC have filed an amended Schedule 13G, reporting a beneficial ownership of 8.1% of Harvard Bioscience Inc.'s common stock.